Literature DB >> 23094880

QT interval and long-term mortality risk in the Framingham Heart Study.

Peter A Noseworthy1, Gina M Peloso, Shih-Jen Hwang, Martin G Larson, Daniel Levy, Christopher J O'Donnell, Christopher Newton-Cheh.   

Abstract

BACKGROUND: The association between QT interval and mortality has been demonstrated in large, prospective population-based studies, but the strength of the association varies considerably based on the method of heart rate correction. We examined the QT-mortality relationship in the Framingham Heart Study (FHS).
METHODS: Participants in the first (original cohort, n = 2,365) and second generation (offspring cohort, n = 4,530) cohorts were included in this study with a mean follow up of 27.5 years. QT interval measurements were obtained manually using a reproducible digital caliper technique.
RESULTS: Using Cox proportional hazards regression adjusting for age and sex, a 20 millisecond increase in QTc (using Bazett's correction; QT/RR(1/2) interval) was associated with a modest increase in risk of all-cause mortality (HR 1.14, 95% CI 1.10-1.18, P < 0.0001), coronary heart disease (CHD) mortality (HR 1.15, 95% CI 1.05-1.26, P = 0.003), and sudden cardiac death (SCD, HR 1.19, 95% CI 1.03-1.37, P = 0.02). However, adjustment for heart rate using RR interval in linear regression attenuated this association. The association of QT interval with all-cause mortality persisted after adjustment for cardiovascular risk factors, but associations with CHD mortality and SCD were no longer significant.
CONCLUSION: In FHS, there is evidence of a graded relation between QTc and all-cause mortality, CHD death, and SCD; however, this association is attenuated by adjustment for RR interval. These data confirm that using Bazett's heart rate correction, QTc, overestimates the association with mortality. An association with all-cause mortality persists despite a more complete adjustment for heart rate and known cardiovascular risk factors.
© 2012, Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 23094880      PMCID: PMC3481183          DOI: 10.1111/j.1542-474X.2012.00535.x

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN: 1082-720X            Impact factor:   1.468


  32 in total

1.  The Framingham Offspring Study. Design and preliminary data.

Authors:  M Feinleib; W B Kannel; R J Garrison; P M McNamara; W P Castelli
Journal:  Prev Med       Date:  1975-12       Impact factor: 4.018

2.  QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest.

Authors:  A Algra; J G Tijssen; J R Roelandt; J Pool; J Lubsen
Journal:  Circulation       Date:  1991-06       Impact factor: 29.690

3.  QT-interval duration and mortality rate: results from the Third National Health and Nutrition Examination Survey.

Authors:  Yiyi Zhang; Wendy S Post; Darshan Dalal; Elena Blasco-Colmenares; Gordon F Tomaselli; Eliseo Guallar
Journal:  Arch Intern Med       Date:  2011-10-24

4.  Resting heart rate as a predictive risk factor for sudden death in middle-aged men.

Authors:  X Jouven; M Zureik; M Desnos; C Guérot; P Ducimetière
Journal:  Cardiovasc Res       Date:  2001-05       Impact factor: 10.787

5.  Prognostic significance of corrected QT and corrected JT interval for incident coronary heart disease in a general population sample stratified by presence or absence of wide QRS complex: the ARIC Study with 13 years of follow-up.

Authors:  Richard S Crow; Peter J Hannan; Aaron R Folsom
Journal:  Circulation       Date:  2003-09-29       Impact factor: 29.690

6.  Heart rate-corrected QT interval prolongation predicts risk of coronary heart disease in black and white middle-aged men and women: the ARIC study.

Authors:  Jacqueline M Dekker; Richard S Crow; Peter J Hannan; Evert G Schouten; Aaron R Folsom
Journal:  J Am Coll Cardiol       Date:  2004-02-18       Impact factor: 24.094

7.  The relationship between QT interval and heart rate during physiological exercise and pacing.

Authors:  F Akhras; A F Rickards
Journal:  Jpn Heart J       Date:  1981-05

Review 8.  Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies.

Authors:  Alicia Montanez; Jeremy N Ruskin; Patricia R Hebert; Gervasio A Lamas; Charles H Hennekens
Journal:  Arch Intern Med       Date:  2004-05-10

9.  Duration of the QT interval and total and cardiovascular mortality in healthy persons (The Framingham Heart Study experience).

Authors:  R J Goldberg; J Bengtson; Z Y Chen; K M Anderson; E Locati; D Levy
Journal:  Am J Cardiol       Date:  1991-01-01       Impact factor: 2.778

10.  The association between the length of the QT interval and mortality in the Cardiovascular Health Study.

Authors:  John Robbins; Jennifer Clark Nelson; Pentti M Rautaharju; John S Gottdiener
Journal:  Am J Med       Date:  2003-12-15       Impact factor: 4.965

View more
  23 in total

1.  Hemodiafiltration beneficially affects QT interval duration and dispersion compared to hemodialysis.

Authors:  Kitti Barta; Árpád Czifra; Csaba Kun; Alida Páll; Julianna Kulcsár; György Paragh; István Lőrincz; Tamás János Padra; Anupam Agarwal; Abolfazl Zarjou; Zarjou Abolfazl; József Balla; Zoltán Szabó
Journal:  Clin Exp Nephrol       Date:  2014-03-04       Impact factor: 2.801

2.  The QT interval is associated with incident cardiovascular events: the MESA study.

Authors:  Roy Beinart; Yiyi Zhang; João A C Lima; David A Bluemke; Elsayed Z Soliman; Susan R Heckbert; Wendy S Post; Eliseo Guallar; Saman Nazarian
Journal:  J Am Coll Cardiol       Date:  2014-11-10       Impact factor: 24.094

3.  Haloperidol inhibits the development of atherosclerotic lesions in LDL receptor knockout mice.

Authors:  Ronald J van der Sluis; Joya E Nahon; Anne Q Reuwer; Miranda Van Eck; Menno Hoekstra
Journal:  Br J Pharmacol       Date:  2015-03-16       Impact factor: 8.739

4.  Protective role of cardiac-specific overexpression of caveolin-3 in cirrhotic cardiomyopathy.

Authors:  So Yeon Kim; Kang Ho Kim; Jan M Schilling; Joseph Leem; Mehul Dhanani; Brian P Head; David M Roth; Alice E Zemljic-Harpf; Hemal H Patel
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-01-21       Impact factor: 4.052

5.  Validation of Polygenic Scores for QT Interval in Clinical Populations.

Authors:  Michael A Rosenberg; Steven A Lubitz; Honghuang Lin; Gulum Kosova; Victor M Castro; Paul Huang; Patrick T Ellinor; Roy H Perlis; Christopher Newton-Cheh
Journal:  Circ Cardiovasc Genet       Date:  2017-10

6.  Optimal QT interval correction formula in sinus tachycardia for identifying cardiovascular and mortality risk: Findings from the Penn Atrial Fibrillation Free study.

Authors:  Parin J Patel; Yuliya Borovskiy; Anthony Killian; Ralph J Verdino; Andrew E Epstein; David J Callans; Francis E Marchlinski; Rajat Deo
Journal:  Heart Rhythm       Date:  2015-11-10       Impact factor: 6.343

7.  Twelve-lead electrocardiogram and mortality in young adults after ischaemic stroke.

Authors:  Jani Pirinen; Jukka Putaala; Karoliina Aarnio; Aapo L Aro; Satu Mustanoja; Juha Sinisalo; Markku Kaste; Elena Haapaniemi; Turgut Tatlisumak; Mika Lehto
Journal:  Eur Stroke J       Date:  2017-03-01

Review 8.  Testosterone replacement therapy and cardiovascular risk.

Authors:  Thiago Gagliano-Jucá; Shehzad Basaria
Journal:  Nat Rev Cardiol       Date:  2019-09       Impact factor: 32.419

9.  Prediction of Drug-Induced Long QT Syndrome Using Machine Learning Applied to Harmonized Electronic Health Record Data.

Authors:  Steven T Simon; Divneet Mandair; Premanand Tiwari; Michael A Rosenberg
Journal:  J Cardiovasc Pharmacol Ther       Date:  2021-03-08       Impact factor: 2.457

10.  Assessing Prescriber Behavior with a Clinical Decision Support Tool to Prevent Drug-Induced Long QT Syndrome.

Authors:  Katy E Trinkley; Jonathan M Pell; Dario D Martinez; Nicola R Maude; Gary Hale; Michael A Rosenberg
Journal:  Appl Clin Inform       Date:  2021-03-10       Impact factor: 2.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.